OSTEOPORE LIMITED — Capital/Financing Update 2025

May 5, 2025

ASX ANNOUNCEMENT

6 May 2025

Osteopore boosts craniofacial implant distribution in Thailand

Highlights

• Osteopore strikes an exclusive 2-year distribution agreement (Agreement) with Peakmed Co., Ltd (Peakmed) to distribute its craniofacial implants in Thailand.

• Thailand-based medical device company Peakmed specialises in distributing surgical instruments and implants across craniomaxillofacial applications.

• Peakmed distributes to approximately 70 hospitals across Thailand, with its customer base signifying a key market for Osteopore’s craniofacial products.

Australian-Singaporean regenerative medicine company Osteopore Limited ( ASX: OSX ; Osteopore or the Company ) – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that the Company has secured an exclusive 2-year Agreement with Peakmed for its craniofacial implants in Thailand.

Thailand-based medical device company Peakmed specialises in the distribution of surgical instruments and implants across craniomaxillofacial (CMF) applications.

Peakmed has a distribution network of 70 hospitals across Thailand with a customer base that includes neurosurgery, ear-nose-throat (ENT) and plastic reconstructive surgeons who perform surgical procedures that could utilise Osteopore products.

ASX ANNOUNCEMENT

Based on published data sourced from Thailand’s National Health Security Office (NHSO), 93,810 brain tumour patients were admitted over 10 years (2005 to 2014).[1]

As one of the Company’s more mature product lines, Osteopore’s neurosurgical implants are focused on treating a range of brain surgeries where bone tissue is removed, such as burr hole and craniotomy procedures.

Thailand’s CMF market is a primary focus for Osteopore due to the significant number of neurosurgical procedures. The Agreement with Peakmed signifies part of the Company’s continuous review of distribution channels to cater for growth.

According to a report published by the Thailand Board of Investment[2] Thailand’s medical device market has a trade value of US$19.93 billion, while its import value was US$5.99 billion in 2020, ranking Thailand second only to Singapore (US$ 9.94 billion).

Commenting on the change in distribution for craniofacial products in Thailand, CEO Dr Yujing Lim, said:

“Thailand is a market of interest for Osteopore due to the potential volume of cases, which helps us to scale.

“While South East Asian countries are known to be price-sensitive, it is a growing market driven by increased healthcare spending and improved access to healthcare.

“Through Peakmed, Osteopore aims to achieve stronger market access, providing us with a solid base to grow from, looking at its customer base and hospital coverage,” said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

1 J Med Assoc Thai Vol. 99 Suppl. 3 2016

2 https://www.boi.go.th/upload/content/Infopack_MedDevice.pdf

ASX ANNOUNCEMENT

For more information, please contact:

Dr Yujing Lim Isaac Stewart Chief Executive Officer Media & Investor Relations Osteopore Limited Purple E: lim_yujing@osteopore.com E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific microstructured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company’s control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company’s Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forwardlooking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute

ASX ANNOUNCEMENT

investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.